Stay updated on Open-Label Surufatinib in EU NET Patients Clinical Trial
Sign up to get notified when there's something new on the Open-Label Surufatinib in EU NET Patients Clinical Trial page.

Latest updates to the Open-Label Surufatinib in EU NET Patients Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision updates: added v3.4.2 and removed v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check19 days agoChange DetectedThe page shows a minor revision update from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check41 days agoChange DetectedRevision entry updated from v3.3.3 to v3.3.4; core study details remain unchanged.SummaryDifference0.0%

- Check63 days agoChange Detected- A consolidated Locations section was added listing study sites across Alabama, California, Georgia, New York, and Texas, with the previous state-specific location headings removed. The page revision was updated to v3.3.3.SummaryDifference0.6%

- Check92 days agoChange DetectedThe page revision tag was updated from v3.2.0 to v3.3.2.SummaryDifference0.0%

- Check99 days agoChange DetectedNotice about potential government funding delays was removed. The core study information remains unchanged.SummaryDifference0.3%

Stay in the know with updates to Open-Label Surufatinib in EU NET Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Open-Label Surufatinib in EU NET Patients Clinical Trial page.